Bioweapons/du update . ready to be a glow worm??

From Leuren Moret:

LISTEN NOW:

This is a HISTORIC two hour interview I did this morning with Dr. Winn Parker on his radio program called "Parker Pathways" with an audience of 2.5 million. Parker is a PHD Medical science researcher who reviewed biomedical grants and patents for the US Govt/Pentagon/WHO/NIH. This interview ties together and exposes the integration of DU/nanoparticle toxicity/depopulation/chemtrails/fluoride/chloramine/nanoparticle
antennas/HAARP/Google "23andMe" programs....

Folks - it is much much much worse than we ever imagined the applications could be. Listen to this interview carefully... it is beyond demonic. There is an urgent need for a Rockefeller-specific bioweapon that is a more efficient exterminator than what theyare ALREADY using on us.

hour 1:

http://arc.republicbroadcasting.org/Parker/08/02/Parker_020308_100000...

hour 2:

http://arc.republicbroadcasting.org/Parker/08/02/Parker_020308_110000...

23andMe

From Wikipedia, the free encyclopedia

23andMe is a privately held biotechnology company based in Mountain View, California[1] that is developing new ways to help people make sense of their own genetic information. In December 2007 several companies, including 23andMe and deCODE, announced the availability of $999 tests for select single nucleotide polymorphisms. Google has invested $3.9M in 23andMe, whose co-founder Anne Wojcicki is married to Google co-founder Sergey Brin. ^[1] Genentech is also reported to have invested in 23andMe.^[2]

Thomas Söderqvist wrote:

There has not been much news about the company yet (see Blaine Bettinger’s blog The Genetic Genealogist and Attila Csordas’ Pimm), but my guess is that we will hear more about it in the near future. Whatever its future prospects, however, it’s already a good example of how converging technologies ... are emerging at the start-up company level.

The marriage between Sergey Brin and Anne Wojcicki is thus not just a romantic Silicon Valley story; it’s also today’s counterpart to traditional politically motivated marital alliances and gives a new meaning to the concept of converging technologies.^[3]

Kevin Kelleher in GigaOM writes: " A case could be made that there is a good reason for Google to make this deal. And although I realize I may end up regretting it, I am going to make that case.... an investment in 23andMe lets Google chart yet another collision coarse [sic] with Microsoft’s ambitions. ... If Google wants to really organize the world information, it needs to consider DNA, the most personal of data. And what 23andMe is purporting to sell is the ultimate in navel gazing."^[2]

[edit] References

1. ^ "Google invests in genetics firm", BBC. Retrieved on 2007-06-28.
2. ^ ^{a b} Kevin Kelleher (May 24, 2007). Google, Sergey and 23andMe: Why it all makes sense. GigaOmniMedia. Retrieved on 2007-06-27.
3. ^ Thomas Söderqvist (20 May 2007). 23andMe and converging technologies. Medical Museion. University of Copenhagen. Retrieved on 2007-06-27.

[edit] See also

• Single Nucleotide Polymorphism
• Maps of American ancestries
• Pharmacogenomics
• Genetic counseling
• Genomics

[edit] External links

• Official website
• Venture Beat story
• mention in "The Genetic Genealogist"
• Wired Magazine article Nov 2007

News Headlines Products Homepage > Products > 23andMe genetic analysis...

Email this page Print in friendly format News by email Your comments 23andMe genetic analysis launches in Europe By Mike Nagle KEYWORDS Analysis and instrumentation LATEST NEWS HEADLINES Lab AutoMation 2008 - the best of the rest Bird flu testing on the cheep Preclinical services news in brief New Bionanoscience dept launched at TU Delft IDT can link your lab to collaborators online GET THE LATEST MARKET REPORTS 23andMe Google Genentech genome All market reports 24/01/2008 - Google funded start up, 23andme, has now launched its gene tests and web-based analysis in Canada and Europe. Having officially launched in the US last November, this is the first time the company's tools have been available outside of that market. 23andMe generate a genetic profile of each customer, which can then be accessed by the individual on the web. As well as explore their ancestry, see what genetic research means for them (for example lactose intolerance, athletic ability, and food preferences) and compare themselves to friends and family members, 23andMe believes the approach could advance the overall understanding of the human genome. "We believe 2008 will be a year in which our understanding of the human genome will increase significantly through international research efforts, and we are eager to continue connecting individuals to this growing knowledge base of genetic information," said Linda Avey, co-founder of 23andMe. "We believe in empowering individuals by helping them understand their genetic make-up and actively engaging them in the development of new ways to accelerate research," said Anne Wojcicki, the other co-founder of the firm. When users sign up to the $1000 (€683) service, they receive a saliva kit, which is then sent away to a contracted lab. Their DNA is then extracted and exposed to a customised SNP (single nucleotide polymorphism) microarray device made by Illumina. Over half a million points in the individual's genome are then read to generate the genetic profile. "We are receiving overwhelming interest in our services outside the US and are pleased to now offer them in Canada and Europe. Our web-based service model has made the European and Canadian offering possible, and we hope to continue to expand our global footprint to additional locations in the future," Avey added. The firm first came to the world's attention when Google invested $3.9m in it. Biotech giant Genentech was also an early investor. 23andMe's name refers to the 23 chromosomes that make up the human genome. This innovative approach led to 23andMe being lauded as a 'Technology Pioneer' by the World Economic Forum (WEF) at the end of last year. The title is given to those companies who have, in the eyes of the WEF, developed a life-changing technology innovation that has the potential for long-term impact on both business and society. Only the most visionary innovators are awareded the coveted status with previous winners including household names such as Google, Mozilla Corporation and Napster. Among this cream of the crop were twelve biotech or health companies. The 39 winners can participate in World Economic Forum activities, including its annual conferences, for two years. That is exactly where 23andMe are this week - the conference is being held between 23 and 28 January in Davos, Switzerland.

See also: http://www.labtechnologist.com/marketreport/results.asp?bquery=Genentech&title=&publisher=&published=&priceInf=1&priceSup=
&region=all&n=1&searchType=advanced&o=DateDesc

Genentech Executive Committee
From left to right: Ian T. Clark; David A. Ebersman; Arthur D. Levinson; Patrick Y. Yang; Susan D. Desmond-Hellmann; Stephen G. Juelsgaard; Richard H. Scheller

Solid Growth Company

A profitable growth company, Genentech has a strong and diverse pipeline with more than 100 projects in development. Our total operating revenues for 2007 were approximately $11.7 billion, an increase of 26 percent from 2006, with total U.S. product sales of approximately $8.5 billion, a 19 percent increase from 2006.